Angiotensin I
Entresto: FDA has expanded indication in chronic heart failure with preserved ejection fraction
The FDA ( US Food and Drug Administration ) has approved the following expanded indication for Entresto ( Sacubitril /...
RNAi therapeutics for treatment of hypertension: sustained reductions in serum angiotensinogen at 12 weeks and reduced blood pressure with single dose of ALN-AGT
Interim results from the ongoing phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen ( AGT...
Farxiga for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes, approved by FDA
Farxiga ( Dapagliflozin ), a sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor, has been approved in the US to reduce...
Effects of Canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Hyperkalaemia is a common complication of type 2 diabetes mellitus ( T2DM ) and limits the optimal use of agents...
Invokana indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes seen in CREDENCE study - European Commission has approved extended
The European Commission ( EC ) has approved the extension of the indication of Invokana ( Canagliflozin ) to include...
COVID-19 and renin angiotensin system blockers
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Renal and cardiovascular effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
Chronic kidney disease ( CKD ) risk is elevated in patients with type 2 diabetes mellitus ( T2DM ). Disease...
Invokana for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease
The SGLT2 inhibitor Canagliflozin ( Invokana ) .... as an adjunct to the standard of care in adults with type...
The combination Sacubitril and Valsartan does not significantly reduce hospitalizations and cardiovascular death in patients with heart failure with preserved ejection fraction
The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on...
PIONEER-HF trial: angiotensin-neprilysin inhibition in acute decompensated heart failure
Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of...
Canagliflozin reduces major cardiovascular events and kidney failure in patients with type 2 diabetes and chronic kidney disease
Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...
PARAGON-HF trial in heart failure patients with preserved ejection fraction: Entresto misses statistical significance on the primary endpoint
The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto...
Lokelma for the treatment of adults with hyperkalaemia: approved in European Union
The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...
CHAMP-HF Registry: medical therapy for heart failure with reduced ejection fraction
Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...
Entresto, a combination of Sacubitril and Valsartan, can be initiated early in hospitalized patients after an acute heart failure episode
Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...
Cardiovascular complications associated with cancer therapy
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...
Angiotensin converting enzyme inhibitors and risk of lung cancer
The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs...
Chymase inhibitor Fulacimstat in patients with left ventricular dysfunction after myocardial infarction: safety and tolerability
The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients...
Heart failure - Cognition- and dementia-related adverse effects with combination of Sacubitril and Valsartan: analysis of the FAERS database
Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor Sacubitril - Valsartan (...
Heart failure with reduced ejection fraction: dementia-related adverse events with angiotensin receptor-neprilysin inhibitor Entresto versus Enalapril
Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction...